DAIC

JUNE 4, 2024

milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product.

Medicare 104

Medicare Plaque Reimbursement Cardiovascular Disease 104

DAIC

JULY 18, 2024

a leader in non-invasive artificial intelligence (AI) heart care solutions, introduced the next generation HeartFlow Plaque Analysis with an interactive experience. Having access to a patient’s whole coronary picture, with both quantified plaque and physiology, is a game changer as a clinician. F.A.C.C.

Coronary Artery Disease 111

Coronary Artery Disease Plaque Technology Medicare 111

DAIC

OCTOBER 16, 2024

15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). tim.hodson Wed, 10/16/2024 - 12:36 Oct. The four contractors for the U.S.

CMS 52

CMS Medicare Plaque Chest Pain 52

DAIC

JUNE 18, 2024

The breakthrough designation, according to the Milpitas, CA-based technology company, is for an indication to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. of the U.S. population.

Coronary Artery Disease 105

Coronary Artery Disease Technology Stents Stent 105

CardiacWire

JUNE 30, 2024

GLP-1s are for CVD too – So far this year GLP-1s have gone from a weight loss and diabetes drug that “might” have cardiovascular benefits to becoming an FDA-approved and Medicare-covered option for CV event reduction. GLP-1s’ cardiovascular impact is likely to continue to expand, given growing evidence that it also improves HF symptoms.

Tricuspid 59

Tricuspid Reimbursement Medicare Electrophysiology 59

DAIC

JANUARY 3, 2024

3 HeartFlow’s FFR CT Analysis is covered by Medicare and for >99% of commercially insured lives. We've experienced a year of notable accomplishments and growth including the expansion of our product portfolio with Plaque Analysis and RoadMap Analysis. said John Farquhar, Chief Executive Officer at HeartFlow.

Coronary Artery Disease 59

Coronary Artery Disease Chest Pain Plaque Technology 59

Stroke Journal

JANUARY 30, 2025

Introduction:Alzheimers Disease (AD), characterized by extracellular deposition of amyloid beta (A) plaques in brain tissue, is often comorbid with cerebral amyloid angiopathy, which carries an elevated risk of intracranial hemorrhage. Stroke, Volume 56, Issue Suppl_1 , Page ATP205-ATP205, February 1, 2025. andICD-10-CMcode G30.x.

Hemorrhage 40

Hemorrhage Medicare Outpatient Inpatient 40